Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Sage Therapeutics (SAGE)
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) Announces R&D Leadership Transition
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (BIIB) (earlier)
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) Reports Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor
-
-
-
-
-
-
-
Raymond James Resumes Sage Therapeutics (SAGE) at Market Perform
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) Files Mixed Shelf
-
-
-
-
-
-
-
TD Cowen Downgrades Sage Therapeutics (SAGE) to Hold
-
466,337 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


